全球人类微生物组市场规模（按产品、应用、地区、范围和预测）

人类微生物组市场规模及预测

2024 年人类微生物组市场规模价值 6.6836 亿美元，预计到 2031 年将达到 28.2857 亿美元，2024 年至 2031 年的复合年增长率为 21.80%。人体微生物群是指生活在人体内和体表的所有微生物（细菌、真菌、病毒和其他微生物）。微生物群包含数兆的微生物。主要部位包括肠道、皮肤、口腔、鼻腔及泌尿生殖道。肠道微生物群是研究最广泛、微生物密度最高的。它在消化、维生素合成和防御病原体中发挥重要作用。微生物群对于帮助消化、调节免疫系统和预防感染等，保持您的健康至关重要。它也会影响情绪、心理健康和疾病的发展。

每个人都有独特的微生物群，受遗传、饮食、环境、年龄和生活方式的影响。它也会因抗生素、疾病和饮食变化等因素而随着时间而改变。

研究微生物组有助于我们瞭解其在肥胖症、糖尿病、发炎性肠道疾病甚至癌症等疾病中的作用。治疗应用包括益生菌、益生元和微生物组移植（例如粪便微生物群移植）。

微生物群与宿主细胞相互作用，有助于代谢功能、免疫反应和体内平衡。菌丛失衡，即微生物群失衡，可导致多种健康问题。

定序技术和生物资讯学的进步极大地提高了我们对人类微生物组的理解。宏基因体学使得无需实验室培养即可研究微生物群落。

瞭解人类微生物组对于开发新的诊断和治疗策略至关重要，凸显了其在个人化医疗和整体健康中的重要性。

全球人类微生物组市场动态

主要市场推动因素

慢性病盛行率增加：

肥胖症、糖尿病和胃肠道疾病等疾病的增加推动了基于微生物组的治疗和诊断的需求。

基因组学和宏基因组学技术的进展：

定序技术和生物资讯学的创新促进了对微生物组的深入分析和理解，从而推动了市场成长。

人们对个人化医疗的兴趣日益浓厚：

针对个人微生物群的个人化治疗和预防方法变得越来越普遍，推动了市场需求。

政府与私人资助：

政府机构和私人组织对微生物组研究的大量投资和资助正在加速市场的发展。

益生菌和益生元产品的扩展：

消费者对益生菌、益生元和促进健康微生物群的营养补充剂的认识和需求不断提高，促进了市场扩张。

抗生素抗药性发生率上升：

抗生素抗药性的上升加速了对抗生素替代疗法的需求，引发了人们对微生物组疗法的兴趣。

人口老化：

全球人口老化使得人们更容易患上慢性疾病和健康状况，这推动了对微生物组相关的健康解决方案的需求。

微生物组研究进展：

正在进行的研究揭示了微生物群与各种健康状况之间的联繫，扩大了潜在的治疗应用，从而推动了市场成长。

主要课题

科学技术的复杂性：

揭示人类微生物组内以及微生物组与宿主之间复杂而动态的相互作用十分复杂。微生物组研究的研究方法标准化仍缺乏。

监管障碍：

针对微生物组相关产品的监管架构仍在发展中。由于该领域的新颖性，获得新疗法和新产品的批准需要时间，并且存在高度的不确定性。

研发成本高：

开发以微生物为基础的治疗和诊断需要在研究、临床试验和技术方面进行大量投资。高成本可能会限制中小企业和新创企业的进入。

知识产权问题：

由于生物材料和过程的性质，保护微生物组领域的智慧财产权可能具有课题性。专利情况仍不明朗，为企业带来不确定性。

有限的临床证据：

儘管人们的兴趣日益浓厚，但证明许多微生物组产品的有效性和安全性的有力临床证据仍然有限。需要进行更大规模、更长期的临床试验来确定可靠性。

微生物组数据的复杂性：

分析和解释微生物组研究产生的大量数据需要先进的生物资讯工具和专业知识。将微生物组数据与其他健康数据结合也是一个课题。

消费者的认知与接受度：

一般消费者对微生物群及其对健康的影响的理解仍在不断发展中。教育消费者并获得他们对微生物相关产品的信任是一项课题。

道德和隐私问题：

微生物组数据的收集和使用引发了道德和隐私问题，特别是在遗传资讯的储存和共享方面。确保遵守资料保护法规非常重要。

主要趋势：

个人化医疗日益受到关註：

根据个人独特的微生物组特征扩大个人化治疗和诊断。将调整治疗方法以提高疗效并减少副作用。

微生物组定序技术的进展：

透过次世代定序 (NGS) 和改进的生物资讯学工具进行更深入、更准确的微生物组分析。降低成本并提高定序技术的可近性。

不断成长的益生菌和益生元市场：

消费者对益生菌、益生元和合生元作为日常膳食补充剂的需求不断增加。透过配方和递送机制的创新来提高功效。

数位健康与人工智慧融合：

使用人工智慧和机器学习来分析复杂的微生物组数据。开发用于微生物组监测和个人化推荐的数位健康平台和应用程式。

基于微生物组的治疗方法的开发：

增加基于微生物组的一系列疾病治疗研究和临床试验，包括胃肠道疾病、代谢紊乱和精神健康问题。与微生物组相关的药物和生物製剂管道正在不断增长。

微生物组诊断的兴起：

开发诊断测试来评估微生物群的健康及其对各种疾病的影响。使用微生物组图谱来早期发现和监测疾病。

合作与伙伴关係：

製药和生物技术公司、研究机构和学术中心之间的策略联盟。合作加速研究、分享数据并开发新产品。

消费者意识与教育：

提高消费者对肠道健康的重要性以及微生物群在整体健康中的作用的认识。进行教育活动和行销活动来推广微生物友善产品。

目录

第 1 章全球人类微生物组市场：简介

• 市场概况
• 调查范围
• 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章全球人类微生物组市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析
• 监管框架

第5章全球人类微生物组市场（依产品划分）

• 概述
• 益生菌
• 食物
• 医疗食品
• 诊断设备
• 药品
• 补充

第6章全球人类微生物组市场（依应用）

• 概述
• 治疗药物
• 诊断剂
• 其他

第7章全球人类微生物组市场（按地区）

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第8章全球人类微生物组市场：竞争格局

• 概述
• 企业市占率
• 供应商情况
• 主要发展策略

第9章 公司简介

• Enterome Bioscience
• E.I. Du Pont De Nemours and Company
• Merck & Co., Inc.
• Metabiomics Corporation
• Yakult Honsha Co., Ltd.
• Microbiome Therapeutics, LLC
• Osel, Inc.
• Second Genome, Inc.
• Vithera Pharmaceuticals
• Vedanta Biosciences, Inc.

第 10 章 附录

• 相关报导

Human Microbiome Market Size And Forecast

Human Microbiome Market size was valued at USD 668.36 Million in 2024 and is projected to reach USD 2828.57 Million by 2031 , growing at a CAGR of 21.80 % from 2024 to 2031. The human microbiome refers to the collection of all the microorganisms (bacteria, fungi, viruses, and other microbes) that live in and on the human body. The microbiome includes trillions of microorganisms. Major sites include the gut, skin, mouth, nose, and urogenital tract. The gut microbiome is the most extensively studied and has the highest microbial density. It plays a crucial role in digestion, synthesizing vitamins, and protecting against pathogens. The microbiome is essential for maintaining health by aiding in digestion, regulating the immune system, and preventing infections. It also influences mood, mental health, and the development of diseases.

Each individual has a unique microbiome influenced by genetics, diet, environment, age, and lifestyle. It can change over time due to factors such as antibiotics, illness, and diet changes.

Studying the microbiome helps in understanding its role in diseases like obesity, diabetes, inflammatory bowel disease, and even cancer. Therapeutic applications include probiotics, prebiotics, and microbiome transplants (e.g., fecal microbiota transplantation).

The microbiome interacts with the host's cells and contributes to metabolic functions, immune responses, and the maintenance of homeostasis. Dysbiosis, an imbalance in the microbiome, can lead to various health issues.

Advances in sequencing technologies and bioinformatics have significantly enhanced the understanding of the human microbiome. Metagenomics allows the study of microbial communities without needing to culture them in the lab.

Understanding the human microbiome is crucial for developing new diagnostic and therapeutic strategies, highlighting its importance in personalized medicine and overall health.

Global Human Microbiome Market Dynamics

The key market dynamics that are shaping the global human microbiome market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases:

The rise in conditions such as obesity, diabetes, and gastrointestinal disorders has heightened the demand for microbiome-based therapies and diagnostics.

Advancements in Genomic and Metagenomic Technologies:

Innovations in sequencing technologies and bioinformatics are facilitating detailed analysis and understanding of the microbiome, driving market growth.

Growing Interest in Personalized Medicine:

Personalized approaches to treatment and prevention, tailored to an individual's microbiome, are gaining traction, boosting market demand.

Government and Private Funding:

Significant investments and grants for microbiome research from both governmental bodies and private organizations are accelerating market development.

Expansion of Probiotic and Prebiotic Products:

Increasing consumer awareness and demand for probiotics, prebiotics, and dietary supplements that promote a healthy microbiome are contributing to market expansion.

Rising Incidence of Antibiotic Resistance:

The need for alternative treatments to antibiotics, due to growing antibiotic resistance, is driving interest in microbiome-based therapies.

Aging Population:

An aging global population, more prone to chronic diseases and health conditions, is increasing the need for microbiome-related health solutions.

Advances in Microbiome Research:

Continuous research uncovering the links between microbiomes and various health conditions is expanding potential therapeutic applications, and fueling market growth.

Key Challenges:

Scientific and Technical Complexities:

Understanding the intricate and dynamic interactions within the human microbiome and between the microbiome and host is complex. Standardization of methodologies for microbiome research is still lacking.

Regulatory Hurdles:

Regulatory frameworks specific to microbiome-based products are still evolving. Obtaining approvals for new therapies and products can be time-consuming and uncertain due to the novelty of the field.

High Research and Development Costs:

Developing microbiome-based therapies and diagnostics involves significant investment in research, clinical trials, and technology. High costs can limit the entry of smaller companies and startups.

Intellectual Property Issues:

Protecting intellectual property in the microbiome space is challenging due to the nature of biological materials and processes. Patent landscapes are still unclear, creating uncertainties for companies.

Limited Clinical Evidence:

While there is growing interest, robust clinical evidence demonstrating the efficacy and safety of many microbiome-based products is still limited. More large-scale, long-term clinical trials are needed to establish credibility.

Complexity of Microbiome Data:

Analyzing and interpreting the vast amounts of data generated from microbiome studies requires advanced bioinformatics tools and expertise. Integrating microbiome data with other health data is also challenging.

Consumer Awareness and Acceptance:

Public understanding of the microbiome and its health implications is still developing. Educating consumers and gaining their trust in microbiome-based products can be challenging.

Ethical and Privacy Concerns:

Collecting and using microbiome data raises ethical and privacy issues, especially concerning the storage and sharing of genetic information. Ensuring compliance with data protection regulations is critical.

Key Trends:

Increased Focus on Personalized Medicine:

Growth in personalized treatments and diagnostics based on an individual's unique microbiome profile. Tailoring therapies to enhance efficacy and reduce side effects.

Advancements in Microbiome Sequencing Technologies:

Improvements in next-generation sequencing (NGS) and bioinformatics tools for deeper and more accurate microbiome analysis. Reduced costs and increased accessibility of sequencing technologies.

Expansion of Probiotics and Prebiotics Market:

Rising consumer demand for probiotics, prebiotics, and synbiotics as part of daily dietary supplements. Innovations in formulation and delivery mechanisms to improve effectiveness.

Integration with Digital Health and AI:

Use of artificial intelligence and machine learning to analyze complex microbiome data. Development of digital health platforms and apps for microbiome monitoring and personalized recommendations.

Microbiome-Based Therapeutics Development:

Increased research and clinical trials focused on microbiome-based treatments for various conditions, including gastrointestinal diseases, metabolic disorders, and mental health issues. A growing pipeline of microbiome-related pharmaceuticals and biologics.

Rise in Microbiome Diagnostics:

Development of diagnostic tests to assess the health of the microbiome and its impact on various diseases. Use of microbiome profiles for early disease detection and monitoring.

Collaborations and Partnerships:

Strategic alliances between pharmaceutical companies, biotech firms, research institutions, and academic centers. Collaborative efforts to accelerate research, share data, and develop new products.

Consumer Awareness and Education:

Increasing public awareness of the importance of gut health and the microbiome's role in overall well-being. Educational campaigns and marketing efforts to promote microbiome-friendly products.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Human Microbiome Market Regional Analysis

Here is a more detailed regional analysis of the global human microbiome market:

North America

North America is significantly dominating the human microbiome market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America, particularly the United States, has a strong infrastructure for biomedical research. Leading research institutions and universities are at the forefront of microbiome studies.

Substantial government and private sector funding for microbiome research and development. Venture capital investments in biotech firms specializing in microbiome-based therapies and diagnostics.

Numerous major pharmaceutical and biotechnology companies are headquartered in North America. Collaboration between large firms and startups to innovate and develop new microbiome products.

Early adoption of cutting-edge sequencing technologies and bioinformatics tools. Continuous innovation in metagenomics, data analysis, and computational biology.

Well-developed healthcare systems with the capacity to integrate and utilize new microbiome-based diagnostics and treatments. High demand for personalized medicine and advanced healthcare solutions.

A supportive regulatory environment with agencies like the FDA actively engaging in the development of guidelines for microbiome products. Clearer regulatory pathways encouraging innovation and market entry.

Growing public awareness of the importance of gut health and the human microbiome. Increasing demand for probiotics, prebiotics, and microbiome-related health products.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the needle-free injection system market investment in healthcare infrastructure and research and development across Asia Pacific countries. Government initiatives to enhance healthcare services and technologies.

Increasing incidence of lifestyle-related diseases such as diabetes, obesity, and gastrointestinal disorders. Demand for innovative treatments and preventive healthcare solutions.

Growth of the biotech and pharmaceutical industries in countries like China, Japan, South Korea, and India. Increase in local and international investments in microbiome research and product development.

A vast and genetically diverse population provides a rich resource for microbiome studies. High potential for personalized medicine and tailored microbiome therapies.

Adoption of cutting-edge technologies in genomic and microbiome research. Establishment of advanced research facilities and collaborations with global institutions.

Growing public awareness of the importance of gut health and the microbiome's role in overall well-being. Increased consumer interest in probiotics, prebiotics, and functional foods.

Implementation of favorable policies and funding schemes to promote biotech and microbiome research. Government support for healthcare innovation and research initiatives.

Rapid economic development and urbanization led to improved healthcare access and spending. Enhanced ability to invest in advanced medical research and technologies.

Global Human Microbiome Market: Segmentation Analysis

The Global Human Microbiome Market is segmented based on Product, Application, And Geography.

Human Microbiome Market, By Product

• Probiotic
• Foods
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements

Based on Product, the market is bifurcated into probiotics, Foods, Medical Foods, Diagnostic Devices, Drugs, and Supplements. The Probiotics segment is showing significant growth in the human microbiome market. Probiotics are a crucial component of the human microbiome market due to their potential to restore gut balance, contribute to overall health, and cater to the growing consumer interest in gut health. As research progresses and innovation continues, we can expect even more diverse and targeted probiotic products to emerge in the market.

Human Microbiome Market, By Application

• Therapeutics
• Diagnostics

Based on Application, the market is bifurcated into Therapeutics and diagnostics. The therapeutics segment dominates due to the rising development and adoption of microbiome-based therapies. Therapeutics involve microbiome-based treatments for various diseases, while diagnostics focus on identifying and monitoring health conditions through microbiome analysis.

Human Microbiome Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Regional Analysis, the Global Human Microbiome Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America lead the global human microbiome market, driven by advanced biotechnological and microbiological research infrastructure. The increasing prevalence of lifestyle diseases and autoimmune disorders further boosts market growth in these regions. In North America, the U.S. holds the largest market share, followed by Canada. In Europe, France, Germany, Spain, and the U.K. dominate the market.

Key Players

• The "Global Human Microbiome Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
• Enterome Bioscience, Seres Therapeutics, Vedanta Biosciences, 4D Pharma, Rebiotix Inc., Second Genome, Synthetic Biologics Inc., Microbiome Therapeutics LLC, uBiome Inc., Ferring Pharmaceuticals, Evelo Biosciences, AOBiome, Osel Inc., Yakult Honsha Co. Ltd.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In September 2022, Seres Therapeutics Inc. completed the submission of its Biologics License Application (BLA) to the FDA for SER-109, aiming to prevent recurrent C. difficile infection (CDI). This innovative treatment is poised to enhance current standards of care for CDI.
• In September 2022, Ferring Pharmaceuticals received a favorable vote from the FDA's Vaccines and Related Biological Products Advisory Committee for RBX2660. This investigational microbiota-based live biotherapeutic aims to reduce the recurrence of C. difficile infection (CDI) following antibiotic treatment.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN MICROBIOME MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HUMAN MICROBIOME MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL HUMAN MICROBIOME MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Probiotic
• 5.3 Foods
• 5.4 Medical Foods
• 5.5 Diagnostic Device
• 5.6 Drugs
• 5.7 Supplements

6 GLOBAL HUMAN MICROBIOME MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Therapeutics
• 6.3 Diagnostics
• 6.4 Other

7 GLOBAL HUMAN MICROBIOME MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL HUMAN MICROBIOME MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Share
• 8.3 Vendor Landscape
• 8.4 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Enterome Bioscience
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 E.I. Du Pont De Nemours and Company
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Merck & Co., Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Metabiomics Corporation
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Yakult Honsha Co., Ltd.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Microbiome Therapeutics, LLC
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Osel, Inc.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Second Genome, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Vithera Pharmaceuticals
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Vedanta Biosciences, Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Reports